Immuneering (IMRX) Net Cash Flow (2020 - 2026)

Immuneering's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$81.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 29045.69% year-over-year to -$81.3 million; the TTM figure through Mar 2026 stood at $11.5 million (up 137.66% YoY), while the FY2025 annual figure was $92.5 million, up 497.66% from the prior year.
• Net Cash Flow was -$81.3 million for Q1 2026 at Immuneering, up from -$98.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $201.2 million in Q3 2025 to a low of -$98.9 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$1.6 million across 5 years, with a median of -$6.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 1485.45% in 2025, then slumped 29045.69% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$3.8 million in 2022, then sank by 128.37% to -$8.6 million in 2023, then retreated by 4.94% to -$9.1 million in 2024, then slumped by 991.71% to -$98.9 million in 2025, then climbed by 17.79% to -$81.3 million in 2026.
• The last three Net Cash Flow figures came in at -$81.3 million (Q1 2026), -$98.9 million (Q4 2025), and $201.2 million (Q3 2025), per Business Quant data.